Sanofi-Aventis Poland

Last updated: 01.06.2015

Address: ul. Bonifraterska 17
00-203 Warszawa

Tel: 022 280 00 00


Company description

Sanofi-aventis is a global healthcare leader

Focused on patients’ needs, sanofi-aventis offers a range of essential healthcare assets, including a broad-based product portfolio and a presence worldwide.

At a glance

2010 sales: €30.384 billion
A broad portfolio of pharmaceutical products: prescription medicines, generics, consumer health care and animal health
World leader in human vaccines
A broad and balanced presence on both traditional and emerging markets
Around 102,000 employees in 100 countries
Group strategy

Our ambition is to become a diversified global healthcare leader. Our strategy is built around three priorities to reach its goals and ensure sustainable growth:

Innovation in Research and Development
Adaptation of Group structures
External growth opportunities

Products and services

Prescription medicines

In 2010, pharmaceutical sales were of €26.676 million driven by the Group’s major prescription products in particular in the field of diabetes, oncology and thrombosis.

Among these, Lantus® confirms its position as the leading brand of insulin on the world market with sales of €3,510 million in 2010, boosted by the success of the SoloSTAR® pen injector. In the United-States, these figures include an accrual related to U.S. health care reform and were impacted by a reduction in inventory.

In January 2011, the FDA updated its ongoing safety review of Lantus®. In addition to the analysis of the four studies published in Diabetologia, the FDA also reviewed results from a five-year diabetic retinopathy clinical trial in patients with Type 2 Diabetes. At this time and based on these data, FDA has not concluded that Lantus increases the risk of cancer.

The range of products in the field of diabetes also includes Apidra® and Amaryl®.

The Group’s other major prescription drugs are Lovenox®, Taxotere®, Plavix®, Aprovel®, Eloxatin®, and Multaq®.

Jevtana®, a new anti-cancer agent, was approved on June 17, 2010 by the FDA following a priority review and launched in the U.S. on July 19, 2010 for patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-based therapy.

Human Vaccines

Sanofi Pasteur, the vaccines division of sanofi-aventis, is a global leader with the world’s broadest range of human vaccines.

Among the major vaccines there are the Polio/Pertussis/Hib vaccines such as Pentacel® and Pentaxim®, along with influenza vaccines (Vaxigrip® et Fluzone®) against seasonal flu, meningitis and pneumonia vaccines (incuding. Menactra®), adult booster vaccines (including Adacel ®) and travel and other endemics vaccines.

Year-to-date consolidated net sales for the Human Vaccines business were of €3,808 million.


In 2010, sales of the generics business grew to €1,534 million, due to acquisitions completed in 2009 and solid organic growth especially in Eastern Europe and Brazil as well as in the U.S where an authorized generic of Ambien®CR was launched during the period.

Consumer Healthcare

Sanofi-aventis is a mayor player in the global market of Consumer Healthcare. In 2010, the sales of this activity reached €2,217 million reflecting the contribution from the acquisitions of Chattem, Nepentes and Oenobiol.

The eight international brands² are: Doliprane®, Essentiale®, No-Spa®, Maalox®, Enterogermina®, Magne B6®, Dorflex®, and Lactacyd®.

Animal Health

Merial, a wholly-owned sanofi-aventis subsidiary is a leading producer of animal health products with Frontline® and Heartgard®. Merial posted net sales of 2,635 million US dollars in 2010.


We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here